OTC Line Extension Restrictions Would Cause Consumer Confusion – CHPA
This article was originally published in The Tan Sheet
Executive Summary
Restricting OTC brand name line extensions would lead to consumer confusion and fewer new product introductions, according to July 9 1comments submitted by the Consumer Healthcare Products Association
You may also be interested in...
Industry/FDA Line Extension Studies Suggested By OTC Division’s Rosebraugh
The industry should partner with the FDA on studies evaluating whether OTC drug line extensions create consumer confusion, according to OTC Division Deputy Director Curtis Rosebraugh, MD
Industry/FDA Line Extension Studies Suggested By OTC Division’s Rosebraugh
The industry should partner with the FDA on studies evaluating whether OTC drug line extensions create consumer confusion, according to OTC Division Deputy Director Curtis Rosebraugh, MD
Industry/FDA Line Extension Studies Suggested By OTC Division’s Rosebraugh
The industry should partner with the FDA on studies evaluating whether OTC drug line extensions create consumer confusion, according to OTC Division Deputy Director Curtis Rosebraugh, MD